NRx Pharmaceuticals, Inc. (NRXP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NRx Pharmaceuticals, Inc. (NRXP) Healthcare & Pipeline Overview

NRx Pharmaceuticals, Inc. is a clinical-stage biotech firm focused on developing innovative treatments for central nervous system disorders and life-threatening pulmonary diseases. With key assets like ZYESAMI and NRX-101, the company targets unmet needs in respiratory failure and bipolar depression, operating in a competitive yet high-growth pharmaceutical landscape.

What Is the Investment Thesis for NRXP?

NRx Pharmaceuticals presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The investment thesis hinges on the successful development and commercialization of its lead drug candidates, particularly ZYESAMI for respiratory failure and NRX-101 for bipolar depression. Key value drivers include positive clinical trial results, regulatory approvals, and strategic partnerships. The company's high gross margin of 50.6% suggests potential profitability upon successful commercialization. However, the company's negative profit margin of -2336.6% reflects significant ongoing R&D expenses and the absence of revenue-generating products. Upcoming clinical trial readouts for NRX-101 and potential regulatory submissions for ZYESAMI represent near-term catalysts. Investors should closely monitor clinical trial data, regulatory decisions, and the company's ability to secure funding to support its operations.

Based on FMP financials and quantitative analysis

NRXP Key Highlights

Market capitalization of $59.7M reflects the company's early stage and speculative nature.

• Gross margin of 50.6% indicates potential for strong profitability upon successful commercialization of its drug candidates.
• Negative profit margin of -2336.6% highlights the significant ongoing R&D expenses and lack of revenue generation.
• Focus on central nervous system disorders and life-threatening pulmonary diseases addresses critical unmet medical needs.
• Lead product candidates, ZYESAMI and NRX-101, target large and growing markets with significant commercial potential.

Who Are NRXP's Competitors?

NRXP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NRXP's Key Strengths?

Novel drug candidates targeting unmet medical needs.

• Proprietary formulations and drug delivery technologies.
• Experienced management team with expertise in drug development.
• Strong intellectual property protection for its products.

What Are NRXP's Weaknesses?

Limited financial resources and reliance on external funding.

• High risk of clinical trial failures and regulatory setbacks.
• Small size and limited infrastructure compared to larger pharmaceutical companies.
• Dependence on a small number of key drug candidates.

What Could Drive NRXP Stock Higher?

Clinical trial results for NRX-101 in bipolar depression.

• Potential regulatory submissions for ZYESAMI for COVID-19 related respiratory failure.
• Progress in securing funding and partnerships to support clinical development.
• Advancements in drug delivery technologies to improve drug efficacy.

What Are the Key Risks for NRXP?

Financial-distress signal — its Altman Z-Score of -14.48 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures and regulatory setbacks.
• Competition from larger pharmaceutical companies with greater resources.
• Generic competition and patent expirations.
• Limited financial resources and reliance on external funding.
• Changes in regulatory requirements and healthcare policies.

What Are the Growth Opportunities for NRXP?

• Expansion into New Therapeutic Areas: NRx Pharmaceuticals has the opportunity to leverage its expertise in drug development to expand into new therapeutic areas within CNS disorders and pulmonary diseases. The global market for CNS therapeutics is projected to reach $150 billion by 2028, while the market for pulmonary disease treatments is expected to reach $45 billion. By diversifying its pipeline, NRx Pharmaceuticals can reduce its reliance on its current lead candidates and increase its long-term growth potential. This expansion could involve developing treatments for conditions such as Alzheimer's disease, Parkinson's disease, or chronic obstructive pulmonary disease (COPD).
• Strategic Partnerships and Collaborations: NRx Pharmaceuticals can accelerate its growth by forming strategic partnerships and collaborations with larger pharmaceutical companies or research institutions. These partnerships can provide access to additional funding, expertise, and resources, enabling the company to advance its pipeline more rapidly. For example, a partnership with a major pharmaceutical company could provide the financial backing needed to conduct large-scale clinical trials or to commercialize its products globally. Collaborations with research institutions could provide access to cutting-edge technologies and scientific expertise.
• Geographic Expansion: NRx Pharmaceuticals has the opportunity to expand its geographic reach beyond the United States. The global market for pharmaceuticals is growing rapidly, particularly in emerging markets such as China and India. By expanding into these markets, NRx Pharmaceuticals can tap into new sources of revenue and increase its overall growth potential. This expansion could involve establishing local subsidiaries, partnering with local distributors, or licensing its products to local companies.
• Orphan Drug Designations: NRx Pharmaceuticals can pursue orphan drug designations for its drug candidates targeting rare diseases. Orphan drug designation provides several benefits, including market exclusivity, tax credits, and reduced regulatory fees. This can make it more attractive for the company to develop and commercialize treatments for rare diseases, which often face limited competition. The market for orphan drugs is growing rapidly, driven by increasing awareness of rare diseases and the availability of new treatments.
• Advancements in Drug Delivery Technologies: NRx Pharmaceuticals can leverage advancements in drug delivery technologies to improve the efficacy and safety of its drug candidates. For example, the company could explore the use of nanoparticles or liposomes to deliver its drugs more directly to the target tissues, reducing side effects and improving therapeutic outcomes. The market for drug delivery technologies is growing rapidly, driven by the increasing demand for more effective and targeted therapies. By adopting these technologies, NRx Pharmaceuticals can differentiate its products from competitors and increase its market share.

What Are NRXP's Competitive Advantages?

• Patent protection for its novel drug candidates.
• Proprietary formulations and drug delivery technologies.
• Clinical data supporting the efficacy and safety of its products.
• Regulatory exclusivity for approved drugs.

What Does NRXP Do?

NRx Pharmaceuticals, Inc., founded in 2015 and headquartered in Wilmington, Delaware, is a clinical-stage pharmaceutical company dedicated to the development of novel therapeutics. The company focuses on addressing unmet medical needs in the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its lead product candidates include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure, and NRX-100 and NRX-101, oral therapeutics designed for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. NRx Pharmaceuticals operates in the high-risk, high-reward biotechnology sector, where success hinges on clinical trial outcomes and regulatory approvals. The company's strategy involves advancing its pipeline through clinical development, seeking partnerships, and potentially commercializing its products upon regulatory clearance. As a relatively small company with only 2 employees, NRx Pharmaceuticals relies heavily on strategic collaborations and outsourcing to manage its research and development activities. The company's future success depends on the successful navigation of the regulatory landscape and the demonstration of clinical efficacy and safety of its drug candidates.

What Products and Services Does NRXP Offer?

• Develops novel therapeutics for central nervous system disorders.
• Creates treatments for life-threatening pulmonary diseases.
• Focuses on clinical-stage pharmaceutical development.
• Conducts clinical trials to evaluate drug efficacy and safety.
• Seeks regulatory approvals for its drug candidates.
• Aims to commercialize its products upon regulatory clearance.
• Researches and develops innovative drug formulations.

How Does NRXP Make Money?

• Develops and patents novel pharmaceutical products.
• Conducts clinical trials to demonstrate efficacy and safety.
• Seeks regulatory approval from agencies like the FDA.
• Out-licenses or commercializes approved products.

What Industry Does NRXP Operate In?

NRx Pharmaceuticals operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The industry is driven by the increasing demand for novel therapeutics to address unmet medical needs. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. NRx Pharmaceuticals focuses on niche areas within CNS disorders and pulmonary diseases, seeking to differentiate itself through innovative approaches and targeted therapies. The biotechnology industry is subject to stringent regulatory oversight by agencies such as the FDA, requiring extensive clinical trials and rigorous safety testing.

Who Are NRXP's Key Customers?

• Patients suffering from central nervous system disorders.
• Patients with life-threatening pulmonary diseases.
• Healthcare providers who prescribe and administer the company's drugs.
• Hospitals and clinics that use the company's products.

The most recent 8 insider filings for NRx Pharmaceuticals, Inc. break down as 1 sales and 7 purchases. On net that is roughly 409K shares acquired (about $725K) — insiders putting money in tends to read as conviction.

Wall Street analysts project NRx Pharmaceuticals, Inc. revenue of about $10.2M for fiscal 2026, with EPS near $-0.48. The estimate reflects 3 contributing analysts.

NRx Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 109.2% below estimates on average.

NRx Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -14.48 places it in the distress zone, a signal of elevated financial risk.

Return on equity for NRx Pharmaceuticals, Inc. stands at 107.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -22.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.29 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -19.4%, the inverse of the P/E and a quick read on earnings relative to price.

NRx Pharmaceuticals, Inc. (NRXP) Valuation Context

Valued at $59.7M, NRXP is classified as a micro-cap stock. Relative to its peer group, NRXP's quantitative score of 19/100 is below the peer average of 73/100.

NRXP Revenue & Earnings Trend

In Q2 2026, NRXP generated $1.1M in top-line revenue, marking a sequential increase of 3.1%. The company recorded a net loss of $16.5M, with diluted EPS of $-0.44. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, NRXP averaged $-0.19 in diluted EPS.

Company Profile

NRx Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wilmington, US. The company is led by CEO Jonathan C. Javitt. NRXP has traded publicly since 2017.

NRXP Financials

NRXP Latest News

NRXP Analyst Consensus

NRXP MoonshotScore

Common Questions About NRXP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources